We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Training Health Care Professional in Detecting BCC on OCT Using E-learning and CUSUM-analysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05634421
Recruitment Status : Not yet recruiting
First Posted : December 2, 2022
Last Update Posted : December 2, 2022
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:
In this study, various health care professionals will follow an E-learning module in which BCC detection on OCT is explained. Thereafter, the participants will test their skill by assessing OCT-scans. Their performance will be monitored using cumulative-sum analysis. After completion, newly trained OCT assessors will test their diagnostic accuracy for BCC detection on OCT in a exploratory study. The trainability, amount of required training and diagnostic accuracy will be compared between dermatologist and non-dermatologists.

Condition or disease Intervention/treatment
Basal Cell Carcinoma Other: E-learning

Detailed Description:

Accurate detection of BCC on OCT requires substantial training and for future implementation of OCT, many OCT assessors need to be trained. Cumulative-sum analysis (CUSUM-analysis) can be used to objectify the competence of OCT assessors and has been previously used to monitor the competence of OCT assessors. Hence CUSUM-analysis may be valuable in training new assessors. A consensus statement from 2021 states that OCT scans should be acquired and interpreted by dermatologists. But this consensus is challenged by various studies in which OCT assessors were non-dermatologists. All non-dermatologist OCT assessors achieved high diagnostic accuracy. In addition, as diagnosis, treatment and follow-up of BCC patients constitute a substantial proportion of the workload of dermatologists, the question arises whether the acquisition of OCT scans and the subsequent assessment thereof could be outsourced to non-dermatologists. This could reduce the workload of the dermatologist, shorten waiting lists and potentially reduce costs.

In an E-learning dermatologists and non-dermatologists will learn about BCC features on OCT as described by Hussain et al. In this E-learning they will learn how to systematically examine an OCT-scan and detect BCC features. They will also be informed on common pitfalls in BCC detection. Thereafter they will start a CUSUM-module containing 400 OCT-scans (50% BCC vs. 50% non-BCC) to monitor cumulative successes and failures in diagnostic assessments. The competence of OCT assessors can be objectified using preset acceptable (16%) and unacceptable error rates (25%). The error rate is defined as the sum of false negative and false positive diagnoses divided by the total number of assessed OCT scans. For all OCT scans, the histologically verified diagnosis based on punch or excision biopsy is available. The OCT assessor will practice until an acceptable performance rate is achieved and maintained (over 50 scans). A secondary objective will be to explore the diagnostic accuracy in terms of sensitivity and specificity. Once an acceptable performance rate is achieved and maintained, assessors will assess a new cohort of 100 OCT scans (50% BCC and 50% non-BCC). Their level of suspicion for BCC will be expressed on a 5-point Likert-Scale. Diagnostic parameters will be compared between dermatologists and non-dermatologists.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Training Health Care Professionals in Detecting Basal Cell Carcinoma on Optical Coherence Tomography Using E-learning and Cumulative Sum Analysis
Estimated Study Start Date : December 1, 2022
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : December 31, 2023

Group/Cohort Intervention/treatment
Dermatologists who have no experience with OCT.
Other: E-learning
The E-learning is under development at the department of Dermatology from MUMC+.

Residents/physicians who have no experience with OCT
Other: E-learning
The E-learning is under development at the department of Dermatology from MUMC+.

Medical students
Medical students who have no experience with OCT
Other: E-learning
The E-learning is under development at the department of Dermatology from MUMC+.

Nurses who have no experience with OCT
Other: E-learning
The E-learning is under development at the department of Dermatology from MUMC+.

Primary Outcome Measures :
  1. Achieving and maintaining an acceptable error rate (16%) for BCC detection on OCT [ Time Frame: Measured before december 31st 2023 ]
  2. Number of practice scans needed in order to achieve an acceptable error rate [ Time Frame: Measured before december 31st 2023 ]
  3. Median time that dermatologists and non-dermatologists need to assess OCT scans [ Time Frame: Measured before december 31st 2023 ]
  4. Diagnostic accuracy of newly trained dermatologists and non-dermatologists expressed as sensitivity, specificity, PPV, NPV and DOR. [ Time Frame: Measured before december 31st 2023 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
The study population will consist of various health care provides; dermatologists, residents/clinical researchers, nurses and medical students. We aim to include at least 5 participants per category of healthcare providers.

Inclusion Criteria:

  • Health care provider or medical student

Exclusion Criteria:

  • Previous experience with OCT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05634421

Layout table for location contacts
Contact: Tom Wolswijk, MD MSc tom.wolswijk@mumc.nl
Contact: Klara Mosterd, MD PhD k.mosterd@mumc.nl

Sponsors and Collaborators
Maastricht University Medical Center
Layout table for additonal information
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT05634421    
Other Study ID Numbers: 2022-3253
First Posted: December 2, 2022    Key Record Dates
Last Update Posted: December 2, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: To be decided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Maastricht University Medical Center:
Optical coherence tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Basal Cell